TNX-2110
TNX-CA-C201
Phase 1 mab terminated
Quick answer
TNX-2110 for Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2 is a Phase 1 program (mab) at Tonix Pharmaceuticals Holding with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Tonix Pharmaceuticals Holding
- Indication
- Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
- Phase
- Phase 1
- Modality
- mab
- Status
- terminated